<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Prosthetic joint infection: Treatment</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Prosthetic joint infection: Treatment</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Prosthetic joint infection: Treatment</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Larry M Baddour, MD, FIDSA, FAHA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Antonia F Chen, MD, MBA</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sandra Nelson, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Keri K Hall, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 12, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Goals for management of prosthetic joint infection (PJI) include alleviation of symptoms and restoration of function [<a href="#rid1">1-5</a>].</p><p>Issues related to treatment of PJI will be reviewed here. Issues related to the epidemiology, clinical manifestations, diagnosis, and prevention of PJIs are discussed separately. (See  <a class="medical medical_review" href="/d/html/7664.html" rel="external">"Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/7667.html" rel="external">"Prevention of prosthetic joint and other types of orthopedic hardware infection"</a>.)</p><p>Issues related to osteomyelitis are discussed separately. (See  <a class="medical medical_review" href="/d/html/7668.html" rel="external">"Nonvertebral osteomyelitis in adults: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/114350.html" rel="external">"Nonvertebral osteomyelitis in adults: Treatment"</a>.)</p><p class="headingAnchor" id="H1723171894"><span class="h1">SURGICAL MANAGEMENT</span></p><p class="headingAnchor" id="H3181835332"><span class="h2">Overview</span><span class="headingEndMark"> — </span>In general, management of PJIs consists of surgery and antimicrobial therapy. The approach depends on the timing and microbiology of infection, condition of the joint and implant, quality of the soft tissue envelope, and individual patient circumstances. </p><p>Whenever possible, initiation of antibiotic therapy should be delayed until specimens for culture are obtained (via joint aspiration, joint debridement, and/or hardware removal).</p><p>Surgical options include debridement and retention of prosthesis, resection arthroplasty with reimplantation (in one or two stages), resection arthroplasty with no reimplantation, or amputation. The choice of surgical approach is based on data from cohort studies [<a href="#rid1">1</a>].</p><p>Patients with a well-fixed prosthesis with no sinus tract within approximately 30 days of prosthesis implantation or &lt;3 weeks of symptom onset may be candidates for debridement and retention of prosthesis, followed by systemic antibiotic therapy guided by microbiologic results [<a href="#rid1">1</a>]. (See <a class="local">'Debridement and retention of prosthesis'</a> below.)</p><p>Patients who do not meet criteria for debridement and retention of prosthesis may be considered for resection arthroplasty with reimplantation (in one or two stages) (see <a class="local">'Resection arthroplasty with reimplantation'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>One-stage exchange arthroplasty consists of prosthesis resection with debridement of soft tissue and bone, patient redraping (as if performing a new surgical procedure, with different instruments), and implantation of a new prosthesis during the same surgery, followed by systemic antibiotic therapy guided by microbiologic results [<a href="#rid1">1</a>]. This procedure has been advocated in patients with an adequate soft tissue envelope, provided microbiology results are known preoperatively and the pathogen(s) are susceptible to antimicrobials with excellent oral bioavailability. One-stage exchange arthroplasty is less commonly performed in the United States as compared to that in Europe. (See <a class="local">'One-stage exchange arthroplasty'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Two-stage exchange arthroplasty consists of prosthesis resection with debridement of soft tissue and bone and placement of a joint spacer with antimicrobial-impregnated cement, followed by systemic antibiotic therapy for four to six weeks, and subsequent implantation of a new prosthesis once the infection is considered controlled [<a href="#rid1">1,6,7</a>]. Two-stage exchange arthroplasty is the most common approach for management of PJI in the United States. (See <a class="local">'Two-stage exchange arthroplasty'</a> below.)</p><p></p><p>Long-term antibiotic suppression may be warranted in patients with residual hardware following surgery (eg, patients who undergo debridement with retention of prosthesis or patients who undergo one-stage exchange arthroplasty). (See <a class="local">'Suppressive therapy'</a> below.) </p><p>Patients who do not meet criteria for reimplantation may warrant permanent resection arthroplasty [<a href="#rid1">1</a>]. This includes nonambulatory patients, patients who are poor candidates for major surgery (including those with limited bone stock or soft tissue coverage), patients with infection due to a highly resistant organism, and patients who failed a previous exchange arthroplasty in whom the risk of subsequent PJI after another implantation is deemed unacceptably high. Patients with total knee arthroplasty infection may undergo permanent resection arthroplasty with arthrodesis [<a href="#rid2">2</a>]. (See <a class="local">'Permanent resection arthroplasty'</a> below.)</p><p>Amputation should be the last option; it may be appropriate for patients who do not meet criteria for the above approaches. (See <a class="local">'Amputation'</a> below.)</p><p class="headingAnchor" id="H2104064972"><span class="h2">Debridement and retention of prosthesis</span><span class="headingEndMark"> — </span>Debridement and retention of prosthesis (also termed "debridement, antibiotics, and implant retention" [DAIR], or "irrigation and debridement with polyethylene liner exchange") may be an appropriate strategy in the following circumstances [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Diagnosis of PJI within approximately 30 days of prosthesis implantation, or within approximately three weeks of symptom onset, in patients with a well-fixed prosthesis with no sinus tract [<a href="#rid8">8</a>]. In such cases, eradication of infection occurs in up to 70 percent of patients [<a href="#rid9">9-12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who are poor surgical candidates for resection arthroplasty; in such cases, the likelihood of relapsed infection is greater than for patients who undergo resection arthroplasty [<a href="#rid1">1,13</a>].</p><p></p><p>Debridement and retention of prosthesis is not an effective strategy if the prosthesis is loose or if a sinus tract is present; in such cases, resection arthroplasty is required for definitive management.</p><p>Debridement should be performed via open arthrotomy to facilitate polyethylene liner exchange; this approach has been associated with better outcomes than arthroscopic lavage (which precludes liner exchange) [<a href="#rid9">9,12</a>]. Extensive soft tissue debridement should be performed, including debridement of the implant surface and behind polyethylene surfaces. In the setting of significant soft tissue infection, more than one debridement may be warranted.</p><p>Following debridement with polyethylene liner exchange and retention of prosthesis, the initial approach to antibiotic therapy depends on the microbiology of infection: </p><p class="bulletIndent1"><span class="glyph">●</span>For patients with staphylococcal PJI who undergo debridement and retention of prosthesis, antibiotic therapy consists of pathogen-specific intravenous therapy in combination with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for the first two to six weeks following debridement  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>) [<a href="#rid1">1,10,11,14</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with staphylococcal infection associated with hip, elbow, shoulder, or ankle PJI, subsequent therapy consists of pathogen-specific oral therapy in combination with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> to complete a total duration of three months [<a href="#rid10">10,11,14-17</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with staphylococcal infection associated with knee PJI, subsequent therapy consists of pathogen-specific oral therapy in combination with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> to complete a total duration of six months [<a href="#rid1">1,18</a>]. </p><p></p><p class="bulletIndent1">Options for oral therapy that may be combined with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> are summarized in the table  (<a class="graphic graphic_table graphicRef119914" href="/d/graphic/119914.html" rel="external">table 2</a>); fluoroquinolones are preferred. <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">Clindamycin</a> should be avoided due to its increased risk of <em>Clostridioides difficile</em> infection [<a href="#rid9">9,10,19</a>]. (See <a class="local">'Use of adjunctive rifampin'</a> below.)</p><p></p><p class="bulletIndent1">For patients with staphylococcal PJI who cannot take <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> because of drug resistance, allergy, toxicity, intolerance, or drug-drug interactions, antibiotic therapy consists of pathogen-specific intravenous therapy for four to six weeks (before transitioning to oral antibiotic suppression, if warranted) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1">In carefully selected cases of staphylococcal PJI managed with debridement, retention of prosthesis, and rifampin-based therapy, eradication of infection can occur in nearly 90 percent of cases; among patients with staphylococcal PJI managed with debridement and retention in the absence of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>, eradication of infection occurs in 50 to 60 percent of cases [<a href="#rid20">20-24</a>]. Risk factors associated with treatment failure include presence of a sinus tract, symptom duration ≥21 days prior to debridement, and lack of a rifampin-based antibiotic regimen [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with PJI due to other pathogens who undergo debridement and retention of prosthesis, antibiotic therapy consists of pathogen-specific intravenous therapy or highly bioavailable oral therapy for four to six weeks  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1">In a retrospective study including more than 460 patients with streptococcal PJI managed with implant retention, this approach was associated with treatment failure in 42 percent of cases [<a href="#rid25">25</a>]. Factors associated with failure included rheumatoid arthritis, late postoperative infection, and bacteremia; factors associated with success included exchange of removable components and treatment for at least 21 days with a beta-lactam agent.</p><p></p><p>Following administration of antibiotic therapy as described above, indefinite antibiotic suppression with an oral regimen may be warranted  (<a class="graphic graphic_table graphicRef119913" href="/d/graphic/119913.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. The decision to use suppressive therapy must be made based on individual clinical circumstances, taking into consideration the nature of the organism and its antimicrobial susceptibility pattern, the potential for implant loosening and loss of bone stock, the nature of soft tissues, the hazards of prolonged antibiotic therapy, candidacy for further orthopedic surgery, and the age and immune status of the patient [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H15429516"><span class="h2">Resection arthroplasty with reimplantation</span><span class="headingEndMark"> — </span>In general, patients with PJI presenting &gt;30 days after prosthesis implantation require prosthesis removal for definitive management [<a href="#rid26">26</a>]. </p><p>Options for surgical management include one-stage or two-stage arthroplasty; resection and reimplantation are performed in one or two procedures. The two-stage procedure is associated with the highest success rates to prevent PJI recurrence and is the preferred procedure in the United States; the one-stage procedure is more commonly performed outside the United States [<a href="#rid1">1,2,15,27,28</a>]. There are no randomized clinical trials comparing outcomes among patients who undergo one-stage or two-stage procedures [<a href="#rid28">28</a>]. Moreover, a relatively small number of patients have been included in case series and comparative investigations to define patients who are candidates for either procedure.</p><p>Candidates for one-stage exchange arthroplasty include patients with all of the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Total hip or knee arthroplasty</p><p class="bulletIndent1"><span class="glyph">●</span>Good soft tissue coverage (in the absence of a sinus tract)</p><p class="bulletIndent1"><span class="glyph">●</span>Good bone stock (no bone grafting anticipated)</p><p class="bulletIndent1"><span class="glyph">●</span>Microbiology known preoperatively</p><p class="bulletIndent1"><span class="glyph">●</span>Pathogen(s) are susceptible to antimicrobials with high oral bioavailability (to facilitate suppressive therapy)</p><p class="bulletIndent1"><span class="glyph">●</span>Immunocompetent</p><p></p><p>Candidates for two-stage exchange arthroplasty include patients with all of the following [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>No prior two-stage exchange arthroplasty for infection (or prior two-stage exchange arthroplasty with other reason for failure); in selected circumstances, more than one two-stage exchange arthroplasty can be successful if the first one fails.</p><p class="bulletIndent1"><span class="glyph">●</span>Delayed reimplantation technically feasible.</p><p class="bulletIndent1"><span class="glyph">●</span>Good functional outcome anticipated.</p><p class="bulletIndent1"><span class="glyph">●</span>Patient able and willing to undergo two surgeries.</p><p></p><p>Patients with sinus tracts, poor soft tissue coverage, and/or difficult to treat pathogen(s) (such as methicillin-resistant staphylococci, enterococci, and <em>Candida</em> species) are typically managed with two-stage exchange arthroplasty.</p><p class="headingAnchor" id="H2834401169"><span class="h3">One-stage exchange arthroplasty</span><span class="headingEndMark"> — </span>One-stage exchange arthroplasty consists of prosthesis resection with debridement of the soft tissue and bone, patient redraping (as if performing a new surgical procedure, with different instruments), followed by implantation of a new prosthesis during the same surgery; many favor the use of antibiotic-impregnated cement to fix the new prosthesis [<a href="#rid1">1,29</a>]. One-stage exchange arthroplasty is less commonly performed in the United States compared with Europe.</p><p>In some circumstances, one-stage exchange arthroplasty is performed inadvertently, such as in the setting of revision for presumed aseptic loosening; in such cases, the diagnosis of PJI is made based on intraoperative cultures [<a href="#rid30">30</a>]. </p><p>Following one-stage exchange arthroplasty, the initial approach to antibiotic therapy depends on the microbiology of infection: </p><p class="bulletIndent1"><span class="glyph">●</span>For patients with staphylococcal PJI who undergo one-stage exchange arthroplasty, antibiotic therapy consists of pathogen-specific intravenous therapy in combination with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for two to six weeks  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>), followed by pathogen-specific oral therapy in combination with rifampin to complete a total duration of three months [<a href="#rid1">1</a>]. Options for oral therapy that may be combined with rifampin include fluoroquinolones, <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>, <a class="drug drug_general" data-topicid="9653" href="/d/drug information/9653.html" rel="external">minocycline</a>, <a class="drug drug_general" data-topicid="9349" href="/d/drug information/9349.html" rel="external">dicloxacillin</a>, and first-generation cephalosporins  (<a class="graphic graphic_table graphicRef119914" href="/d/graphic/119914.html" rel="external">table 2</a>). (See <a class="local">'Use of adjunctive rifampin'</a> below.)</p><p></p><p class="bulletIndent1">For patients with staphylococcal PJI who cannot take <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> because of drug resistance, allergy, toxicity, or intolerance, antibiotic therapy consists of pathogen-specific intravenous therapy for four to six weeks [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with PJI due to other pathogens who undergo one-stage exchange arthroplasty, antibiotic therapy consists of pathogen-specific intravenous therapy or highly bioavailable oral therapy for four to six weeks  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. </p><p></p><p>Thereafter, indefinite oral antibiotic suppression may be warranted  (<a class="graphic graphic_table graphicRef119913" href="/d/graphic/119913.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. Determination regarding use of suppressive therapy must be made based on individual clinical circumstances, taking into consideration the nature of the organism and its antimicrobial susceptibility pattern, whether cultures are positive at the time of the one-stage revision, the potential for implant loosening and loss of bone stock, the nature of soft tissues, the hazards of prolonged antibiotic therapy, candidacy for further orthopedic surgery, and the immune status of the patient. </p><p>In selected case series, eradication of infection occurs in approximately 80 percent of patients who undergo one-stage exchange arthroplasty [<a href="#rid24">24,31</a>]. In one systematic review including 22 articles and more than 960 patients who underwent single-stage revision arthroplasty of an infected hip or knee joint, recurrent infection was observed in up to 18 percent of patients at ≤2 years follow-up [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H15429531"><span class="h3">Two-stage exchange arthroplasty</span><span class="headingEndMark"> — </span>A two-stage exchange arthroplasty consists of:</p><p class="bulletIndent1"><span class="glyph">●</span>Stage 1: Prosthesis resection with debridement of soft tissue and bone and placement of an antibiotic-impregnated spacer, followed by systemic antibiotic therapy for four to six weeks.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stage 2: Implantation of new prosthesis; the need for additional antibiotic therapy is determined by cultures obtained at the time of reimplantation [<a href="#rid1">1,6,7</a>]. </p><p></p><p>Eradication of infection occurs in more than 85 percent of patients who undergo two-stage exchange [<a href="#rid24">24,32,33</a>].</p><p class="headingAnchor" id="H2270895306"><span class="h4">Stage one</span><span class="headingEndMark"> — </span>Stage one consists of prosthesis resection with debridement of soft tissue and bone and placement of a spacer, followed by systemic antibiotic therapy for four to six weeks. We favor a two-week interval off of antibiotic therapy prior to hardware removal, to improve the diagnostic yield of operative cultures.</p><p>Antibiotic-impregnated cement spacers are commonly used in between stages; it is uncertain whether this practice confers additional benefit beyond the benefit associated with systemic antibiotic therapy [<a href="#rid1">1,34-39</a>]. Most commercially available antibiotic-impregnated cements are prepared with aminoglycosides, which have activity against gram-negative organisms. In the setting of infection due to gram-positive organisms, it may be appropriate to mix <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> with a commercial preparation containing an aminoglycoside [<a href="#rid40">40</a>].</p><p>A static or articulating spacer may be used; the choice does not appear to influence infection-related outcomes [<a href="#rid41">41</a>]. Use of an articulating spacer may permit earlier ambulation, increased range of motion, and may allow for a more extended antibiotic-free period prior to hardware reimplantation; use of a static spacer may limit range of motion and lead to muscle atrophy and arthrofibrosis [<a href="#rid6">6,7</a>]. </p><p>Following removal of the infected prosthesis, antimicrobials with activity against the infecting organism(s) are typically administered for four to six weeks  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. </p><p>It is can be difficult to know whether eradication of infection has been achieved following completion of systemic antimicrobial. The optimal approach to evaluating for signs of infection is uncertain [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>We favor checking inflammatory markers (erythrocyte sedimentation rate or C-reactive protein) after completing antibiotics, prior to new prosthesis implantation [<a href="#rid1">1</a>]. Persistently elevated inflammatory markers without an alternative explanation should prompt workup for persistent infection (including repeat aspiration, frozen section, radiographic imaging, and/or open biopsy and culture) prior to reimplantation. However, the correlation between persistently elevated inflammatory markers and likelihood of residual infection at the time of new prosthesis implantation is not clear [<a href="#rid5">5,42-44</a>]. (See <a class="local">'Monitoring during treatment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some favor obtaining synovial fluid culture to assess sterilization of the joint space following an observation period (at least two weeks) off all antimicrobials prior to new prosthesis implantation; others favor proceeding with new prosthesis implantation immediately following completion of antimicrobials if there are no clinical signs of infection [<a href="#rid1">1</a>]. In general, we favor obtaining synovial fluid cultures in selected cases when there is clinical concern regarding the presence of persistent infection. Molecular methods are promising but thus far, data are insufficient to support routine use of this tool [<a href="#rid45">45</a>]. Patients with known or suspected residual infection should undergo further debridement with spacer exchange and further antimicrobial therapy [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1">In one retrospective study including more than 250 patients with PJI who underwent two-stage exchange arthroplasty, the risk of failure was increased among patients with a positive culture at reimplantation (45 vs 21 percent) [<a href="#rid46">46</a>]. In another retrospective study including more than 150 patients with PJI, the presence of positive cultures obtained at the time of new prosthesis implantation was not associated with a worse outcome [<a href="#rid47">47</a>]. </p><p></p><p class="headingAnchor" id="H1039393924"><span class="h4">Stage two</span><span class="headingEndMark"> — </span>Stage two consists of new prosthesis implantation. Arthrotomy is performed with operative inspection, collection of cultures and frozen section histology [<a href="#rid48">48</a>]. If frozen section is negative, hardware reimplantation may be performed. If frozen section is positive, then a determination of whether or not to proceed with implantation of new hardware must be made; intraoperative findings are important in such decision-making. </p><p>If there are no apparent signs of infection, the new prosthesis may be implanted; many favor the use of antibiotic-impregnated cement to fix the new prosthesis [<a href="#rid1">1</a>]. Empiric antibiotic therapy (guided by culture data obtained at the time of the original resection and at the time of reimplantation) should be administered pending final operative culture results.</p><p>Patients with positive cultures at the time of reimplantation should be managed with reinstitution of antimicrobial therapy to complete another treatment course, followed by chronic suppressive antimicrobial therapy. Patients with negative cultures at the time of reimplantation do not require further antimicrobial therapy.</p><p class="headingAnchor" id="H3815404"><span class="h2">Permanent resection arthroplasty</span><span class="headingEndMark"> — </span>Permanent resection arthroplasty may be appropriate for patients who must undergo resection for management of infection, but who do not meet criteria for reimplantation or for whom reimplantation does not offer a significant functional improvement (such as patients who are nonambulatory for other reasons) [<a href="#rid1">1</a>]. Such patients may include nonambulatory patients, patients who are poor candidates for major surgery (including those with limited bone stock or soft tissue coverage), patients with infection due to highly resistant organisms, and patients who failed a previous exchange in whom the risk of recurrent infection after another implantation is deemed unacceptably high.</p><p>Patients with total hip arthroplasty infection may undergo permanent resection arthroplasty without arthrodesis (Girdlestone procedure); this is frequently associated with limb length discrepancy [<a href="#rid49">49</a>]. Retention of a prosthetic spacer may be associated with a reasonable outcome, based on limited data [<a href="#rid50">50</a>].</p><p>Patients with total knee arthroplasty infection may undergo permanent resection with arthrodesis; approaches include intramedullary nailing or external fixation (with or without placement of an antibiotic cement spacer) [<a href="#rid2">2</a>]. In such cases, adequate bone must be present to create a fusion, and the limb will be shorter than the contralateral limb. Patients will not have knee mobility, but the limb will be preserved.</p><p>Following permanent resection arthroplasty, a four- to six-week course of pathogen-directed parenteral antimicrobial therapy or highly oral bioavailable agent should be administered  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>) [<a href="#rid51">51</a>]. </p><p>Eradication of infection occurs in 60 to 100 percent of patients who undergo permanent resection arthroplasty, which is lower than the reported efficacy of two-stage exchange arthroplasty [<a href="#rid1">1</a>]. An increased risk of reinfection has been observed among patients with a preoperative sinus tract who undergo resection hip or knee arthroplasty with placement of a permanent joint spacer (either fully constructed of polymethylmethacrylate or with new prostheses); in one cohort study including 51 such patients, administration of antimicrobial suppression therapy did not prevent subsequent PJI [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H1512104850"><span class="h2">Amputation</span><span class="headingEndMark"> — </span>Amputation may be warranted in the following circumstances (any of the following) [<a href="#rid1">1</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Necrotizing fasciitis </p><p class="bulletIndent1"><span class="glyph">●</span>Severe bone loss</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate soft tissue coverage</p><p class="bulletIndent1"><span class="glyph">●</span>Failed prior attempt of resection arthroplasty or arthrodesis to control infection</p><p class="bulletIndent1"><span class="glyph">●</span>Functional benefit to amputation over resection arthroplasty or arthrodesis</p><p></p><p>For patients in whom all infected bone and soft tissue was resected in the absence of bacteremia or sepsis, pathogen-specific antimicrobial therapy should administered for 24 to 48 hours following amputation  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>). </p><p>For patients with bacteremia or sepsis, the duration of therapy should be guided by these conditions (see separate topics). </p><p>For patients with residual infected bone and/or soft tissue, a four- to six-week course of pathogen-directed parenteral antimicrobial therapy or highly oral bioavailable agent should be administered  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/114350.html" rel="external">"Nonvertebral osteomyelitis in adults: Treatment"</a>.)</p><p class="headingAnchor" id="H3070754880"><span class="h2">Patients who are not surgical candidates</span><span class="headingEndMark"> — </span>Antimicrobial therapy without accompanying surgery most often results in a delay in appropriate management and confusion regarding the microbiologic diagnosis. Therefore, this approach is warranted only for patients unable to undergo even a single surgical procedure [<a href="#rid2">2</a>]. </p><p>In such cases, joint aspiration for microbiologic studies should be performed prior to initiation of antibiotics. Depending on culture results, patients should receive four to six weeks of pathogen-directed intravenous or highly bioavailable oral antimicrobial therapy  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>). (See <a class="local">'Definitive therapy'</a> below.) </p><p>Thereafter, indefinite antibiotic suppression with an oral regimen is warranted  (<a class="graphic graphic_table graphicRef119913" href="/d/graphic/119913.html" rel="external">table 3</a>). (See <a class="local">'Suppressive therapy'</a> below.)</p><p class="headingAnchor" id="H10"><span class="h1">ANTIBIOTIC THERAPY</span><span class="headingEndMark"> — </span>Whenever possible, initiation of antibiotic therapy should be delayed until specimens for culture are obtained (via joint aspiration, joint debridement, and/or hardware removal).</p><p>In general, management of prosthetic joint infection usually includes a prolonged course of intravenous antibiotic therapy. Data regarding use of oral antibiotic therapy are emerging [<a href="#rid53">53</a>]. (See  <a class="medical medical_review" href="/d/html/114350.html" rel="external">"Nonvertebral osteomyelitis in adults: Treatment", section on 'Systemic therapy'</a>.)</p><p>Suggested antibiotic regimens are outlined in the table  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>). Antibiotic therapy should be tailored to culture and susceptibility data when available.</p><p class="headingAnchor" id="H11"><span class="h2">Empiric therapy</span><span class="headingEndMark"> — </span>For patients with PJI who present with sepsis or are otherwise too unstable to wait for culture data to guide therapy, empiric antibiotic therapy may be justified.</p><p>In such cases, empiric treatment of PJI should include activity against staphylococci (including methicillin-resistant strains) and aerobic gram-negative bacilli. Reasonable regimens include <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> in combination with a third- or fourth-generation cephalosporin  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>).</p><p>Antibiotic therapy should be tailored to culture and susceptibility data when available.</p><p class="headingAnchor" id="H12"><span class="h2">Definitive therapy</span><span class="headingEndMark"> — </span>The approach to antimicrobial therapy (including duration of therapy) depends on the surgical approach, as discussed above. (See <a class="local">'Surgical management'</a> above.) </p><p>Antimicrobial therapy should be tailored to culture data, as discussed in the following sections. </p><p class="headingAnchor" id="H13"><span class="h3">Staphylococci</span></p><p class="headingAnchor" id="H1308667910"><span class="h4">Staphylococcus aureus</span><span class="headingEndMark"> — </span>In general, definitive therapy for treatment of PJI due to <em>S. aureus</em> consists of parenteral antibiotic therapy; regimens are summarized in the table  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>). In addition, use of adjunctive agents for treatment of <em>S. aureus</em> PJI may be warranted in some circumstances. (See <a class="local">'Use of adjunctive rifampin'</a> below.)</p><p>Parenteral agents with activity against methicillin-sensitive <em>S. aureus</em> (MSSA) include <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a>, <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a>, and <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a>  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>). <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">Ceftriaxone</a> may be as effective as other anti-staphylococcal beta-lactams for treatment of oxacillin-susceptible staphylococcal PJIs, based on retrospective data [<a href="#rid47">47,54</a>].</p><p>For outpatient antimicrobial therapy, treatment with <a class="drug drug_general" data-topicid="9674" href="/d/drug information/9674.html" rel="external">nafcillin</a> or <a class="drug drug_general" data-topicid="9724" href="/d/drug information/9724.html" rel="external">oxacillin</a> may be continued via infusion pump; alternatively, treatment with <a class="drug drug_general" data-topicid="9214" href="/d/drug information/9214.html" rel="external">cefazolin</a> may allow greater convenience. In one retrospective study, outpatient treatment of serious MSSA infections with cefazolin was associated with fewer drug emergent effects (12 versus 31 percent) and premature discontinuations (7 versus 34 percent) compared with nafcillin [<a href="#rid55">55</a>].</p><p>Patients with an MSSA infection and a history of type I hypersensitivity (anaphylaxis) to beta-lactams can be treated with either <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> or <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a> [<a href="#rid1">1</a>]. Use of <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a> is limited by risks of myelosuppression, peripheral neuropathy, and optic neuritis.</p><p>The antibiotic of choice for treatment of PJI due to methicillin-resistant <em>S. aureus</em> (MRSA) is <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>; it is the antibiotic agent for which there is the greatest cumulative clinical experience, although there are no controlled trials. Acceptable alternative agents to vancomycin for treatment of PJI due to MRSA include <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a> (and teicoplanin, where available). </p><p>Use of adjunctive agents for treatment staphylococcal PJI may be warranted in some circumstances. (See <a class="local">'Use of adjunctive rifampin'</a> below.)</p><p>Antibiotic agents that warrant further study for treatment of staphylococcal PJI include <a class="drug drug_general" data-topicid="16088" href="/d/drug information/16088.html" rel="external">ceftaroline</a>, <a class="drug drug_general" data-topicid="9535" href="/d/drug information/9535.html" rel="external">telavancin</a>, and <a class="drug drug_general" data-topicid="95502" href="/d/drug information/95502.html" rel="external">dalbavancin</a> [<a href="#rid56">56</a>]. We do not favor use of <a class="drug drug_general" data-topicid="9785" href="/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, <a class="drug drug_general" data-topicid="10283" href="/d/drug information/10283.html" rel="external">linezolid</a>, <a class="drug drug_general" data-topicid="96001" href="/d/drug information/96001.html" rel="external">tedizolid</a>, <a class="drug drug_general" data-topicid="9275" href="/d/drug information/9275.html" rel="external">clindamycin</a>, fluoroquinolones, <a class="drug drug_general" data-topicid="9515" href="/d/drug information/9515.html" rel="external">quinupristin-dalfopristin</a>, or <a class="drug drug_general" data-topicid="9458" href="/d/drug information/9458.html" rel="external">tigecycline</a> for definitive treatment of PJI due to <em>S. aureus</em> [<a href="#rid1">1,14,57,58</a>]. (See  <a class="medical medical_review" href="/d/html/114350.html" rel="external">"Nonvertebral osteomyelitis in adults: Treatment"</a> and  <a class="medical medical_review" href="/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p class="headingAnchor" id="H451830775"><span class="h4">Coagulase-negative staphylococci</span><span class="headingEndMark"> — </span>Most coagulase-negative staphylococci are methicillin resistant (an exception is <em>Staphylococcus lugdunensis</em>, which is almost universally methicillin susceptible). (See  <a class="medical medical_review" href="/d/html/3155.html" rel="external">"Staphylococcus lugdunensis"</a>.)</p><p>In general, the approach to treatment of PJI due to coagulase-negative staphylococci is the same as the approach for treatment of PJI due to <em>S. aureus.</em> (See <a class="local">'Staphylococcus aureus'</a> above.)</p><p>Empiric treatment for PJI due to coagulase-negative staphylococci should consist of an agent with activity against methicillin-resistant staphylococci. If susceptibility testing demonstrates methicillin susceptibility, a beta-lactam with activity against methicillin-susceptible staphylococci should be used  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1283764106"><span class="h4">Use of adjunctive rifampin</span><span class="headingEndMark"> — </span>For patients with staphylococcal PJI and residual hardware following surgery (eg, patients who undergo debridement with retention or patients who undergo one-stage exchange), we favor the use of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (in combination with at least one other anti-staphylococcal agent)  (<a class="graphic graphic_table graphicRef119914" href="/d/graphic/119914.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>). (See <a class="local">'Debridement and retention of prosthesis'</a> above and <a class="local">'One-stage exchange arthroplasty'</a> above.) </p><p><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> has activity against microorganisms in biofilms, which are important in the pathophysiology of staphylococcal osteomyelitis (particularly in the setting of hardware) [<a href="#rid10">10,14,59</a>]. (See  <a class="medical medical_review" href="/d/html/7664.html" rel="external">"Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Biofilm'</a>.)</p><p>There are no data from large, randomized trials evaluating the efficacy of adjunctive <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> for treatment of PJI [<a href="#rid60">60</a>]. In one systematic review and meta-analysis including 64 studies and more than 4000 patients with staphylococcal hip and/or knee PJI managed with debridement and prosthesis retention, the pooled risk ratio for efficacy of rifampin effectiveness was 1.10 (95% CI 1.00-1.22), suggesting rifampin may provide only modest benefit for prevention of treatment failure [<a href="#rid60">60</a>]. </p><p>Rapid emergence of resistance in the setting of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> monotherapy is common. Therefore, rifampin should be initiated several days after surgical debridement and initiation of anti-staphylococcal therapy (eg, once the burden of organisms has been reduced). Rifampin should be coadministered with another active antibacterial agent. </p><p><a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">Rifampin</a> has significant drug-drug interactions and a high risk of toxicity; careful consideration of an individual's medications and comorbidities (particularly history of liver disease) is warranted prior to initiation of rifampin.</p><p class="headingAnchor" id="H1717077881"><span class="h3">Gram-negative bacilli</span><span class="headingEndMark"> — </span>For treatment of PJI due to gram-negative organisms, we favor fluoroquinolones (if susceptibility testing confirms sensitivity) since they have high bone penetration with oral administration. Other antibiotics for treatment of PJI due to gram-negative organisms include parenteral beta-lactams and carbapenems. Antibiotic dosing is summarized in the table  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>).</p><p>PJIs due to <em>Pseudomonas aeruginosa</em> are difficult to cure, even with debridement and hardware removal. Agents with activity against <em>P. aeruginosa</em> include <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, <a class="drug drug_general" data-topicid="9554" href="/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="9226" href="/d/drug information/9226.html" rel="external">ceftazidime</a>, <a class="drug drug_general" data-topicid="9215" href="/d/drug information/9215.html" rel="external">cefepime</a>, and <a class="drug drug_general" data-topicid="9613" href="/d/drug information/9613.html" rel="external">meropenem</a>  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2577923284"><span class="h3">Enterococci</span><span class="headingEndMark"> — </span>Treatment for enterococcal PJI should be tailored to susceptibility results. It is unclear whether combination therapy is superior to monotherapy [<a href="#rid61">61</a>]. We favor combination therapy in the setting of retained hardware; the regimen of <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a> and <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is generally well tolerated [<a href="#rid62">62</a>]. However, if antibiotic-impregnated material containing <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> is implanted at the time of debridement, monotherapy is likely sufficient; in such cases, we favor treatment with intravenous ampicillin or penicillin.</p><p>The treatment of choice for penicillin-resistant enterococcal PJI is <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>; acceptable alternative agents to include <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a> (and teicoplanin, where available) [<a href="#rid1">1</a>]. </p><p class="headingAnchor" id="H3926746886"><span class="h3">Streptococci</span><span class="headingEndMark"> — </span>The treatment of choice for streptococcal PJI is penicillin or <a class="drug drug_general" data-topicid="8737" href="/d/drug information/8737.html" rel="external">ampicillin</a>  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>) [<a href="#rid63">63</a>]. <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">Ceftriaxone</a> is an equally acceptable agent and is favored for dosing convenience in the outpatient setting. Patients allergic to beta-lactams may be treated with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a>.</p><p class="headingAnchor" id="H20600487"><span class="h3">Cutibacterium acnes</span><span class="headingEndMark"> — </span>Shoulder infection is the most common presentation of PJI due to <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>)<em> acnes. </em>Options for treatment of infection due to <em>C. acnes</em> include penicillin or <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>); patients allergic to beta-lactams may be treated with <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/d/html/5538.html" rel="external">"Invasive Cutibacterium (formerly Propionibacterium) infections"</a>.)</p><p class="headingAnchor" id="H336892937"><span class="h3">Fungi</span><span class="headingEndMark"> — </span>Management of fungal PJI is discussed separately. (See  <a class="medical medical_review" href="/d/html/2466.html" rel="external">"Candida osteoarticular infections"</a>.)</p><p class="headingAnchor" id="H1119421955"><span class="h3">Culture-negative</span><span class="headingEndMark"> — </span>The most common cause of culture-negative PJI is administration of antibiotic therapy prior to collection of specimens for culture [<a href="#rid64">64</a>]. Other causes include infection with a pathogen that cannot be identified using routinely available methods and noninfectious mimic of PJI [<a href="#rid2">2</a>]. Techniques for identifying a pathogen in culture-negative PJI are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7664.html" rel="external">"Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Culture-negative infection'</a>.)</p><p>Patients with culture-negative PJIs should receive antimicrobial agents with activity against gram-positive and gram-negative pathogens. (See <a class="local">'Empiric therapy'</a> above.)</p><p>Patients with culture-negative PJI have similar outcomes as patients with positive cultures following standard treatment regimens. In a retrospective study including 60 patients with PJI and negative cultures, five-year survival free of treatment failure was 94 percent in patients treated with two-stage exchange arthroplasties and 71 percent in patients who underwent debridement with retention of their prosthesis [<a href="#rid64">64</a>].</p><p class="headingAnchor" id="H710620619"><span class="h2">Suppressive therapy</span><span class="headingEndMark"> — </span>Long-term oral antibiotic suppression may be warranted for patients with PJI and residual hardware following surgery (eg, patients who undergo debridement with retention or patients who undergo one-stage exchange). (See <a class="local">'Debridement and retention of prosthesis'</a> above and <a class="local">'One-stage exchange arthroplasty'</a> above.)</p><p>Decisions regarding the use and duration of suppressive therapy must be made based on individual clinical circumstances, taking into consideration the pathogen and its antimicrobial susceptibility pattern, the potential for implant loosening and loss of bone stock, the characteristics of soft tissues, the hazards of prolonged antibiotic therapy, candidacy for further orthopedic surgery, and age and immune status of the patient [<a href="#rid1">1</a>]. </p><p>Options for suppressive therapy are summarized in the table  (<a class="graphic graphic_table graphicRef119913" href="/d/graphic/119913.html" rel="external">table 3</a>). The optimal duration of suppressive therapy is uncertain. Many favor at least three to six months of therapy; some favor indefinite therapy [<a href="#rid2">2</a>]. Individual patient factors (such as clinical course, microbiology, patient preference) may impact the duration of suppressive therapy. </p><p>Suppressive oral antibiotic therapy typically postpones rather than prevents treatment failure [<a href="#rid9">9,23,47</a>]. Studies evaluating use of suppressive oral antibiotic therapy include:</p><p class="bulletIndent1"><span class="glyph">●</span>An observational study including 108 patients with knee implant infection managed with debridement, hardware retention, and initial intravenous antibiotic therapy followed by an extended course of oral antibiotic therapy; treatment failure rates were comparable among those treated less than 12 months and those treated longer than 12 months [<a href="#rid65">65</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial including more than 100 patients with PJI managed with two-stage exchange arthroplasty, followed by randomization to three months of oral antibiotic suppressive therapy or no further antibiotic treatment; repeat infection during 24-month follow-up occurred less frequently among patients treated with suppressive antibiotics (5 versus 19 percent) [<a href="#rid66">66</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A cohort study including more than 130 patients with retained PJI; oral antibiotic suppressive therapy was effective and well-tolerated during two years of follow-up in 61 percent of cases [<a href="#rid67">67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A cohort study including more than 80 patients with orthopedic infection in the setting of retained hardware; oral antibiotic suppressive therapy was successful among those treated for three months but not among those treated for six months [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A retrospective review including more than 90 patients with PJI; the infection-free rate at five years was greater among those who received oral antibiotic suppressive therapy for at least six months than among those who did not (68 versus 41 percent) [<a href="#rid69">69</a>].</p><p></p><p class="headingAnchor" id="H494845363"><span class="h2">Duration of therapy</span><span class="headingEndMark"> — </span>The duration of antimicrobial therapy for treatment of PJI is tailored to the surgical management, as discussed above. (See <a class="local">'Surgical management'</a> above.)</p><p>In general, management of complex orthopedic infections usually includes a prolonged course of intravenous antibiotic therapy; data regarding shortened antibiotic duration and use of oral antibiotic therapy are emerging [<a href="#rid53">53</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a randomized trial including 410 patients with PJI who underwent surgery and initial intravenous antibiotic treatment (mean duration 9 days; range 5 to 15 days) followed by a course of oral antibiotic therapy (in the absence of long-term suppressive therapy), persistent infection within 2 years after completing treatment was observed more frequently among patients who received 6 weeks of antibiotic therapy than among those who received 12 weeks of antibiotic therapy (18.1 versus 9.4 percent; risk difference 8.7 percentage points, 95% CI 1.8-15.6); thus, noninferiority was not shown [<a href="#rid70">70</a>]. The difference in risk was greatest among patients who underwent debridement with prosthesis retention (30.7 versus 14.5 percent; risk difference 16.2 percentage points, 95% CI 2.9-29.5). These data are important as we strive to define the optimal approach for management of PJI.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In one meta-analysis including 10 studies (9 observational studies and 1 randomized trial) and more than 850 patients with PJI managed with debridement and retention or two-stage exchange arthroplasty, no significant difference between short-course and long-course antibiotics was observed (relative risk 0.87, 95% CI 0.62-1.22) [<a href="#rid71">71</a>]. The generalizability of these findings is limited; further study is needed. </p><p></p><p class="headingAnchor" id="H591587722"><span class="h1">MONITORING DURING TREATMENT</span><span class="headingEndMark"> — </span>During treatment, patients should be monitored for clinical response and for adverse effects of therapy.</p><p class="headingAnchor" id="H112725446"><span class="h2">Clinical response</span><span class="headingEndMark"> — </span>The clinical response to treatment is monitored via examination of the joint and wound.</p><p>We typically see patients for follow-up examination every two weeks initially and then every three months to monitor response. Most patients will have significant improvement in pain, edema, and erythema of the joint within 6 to 12 weeks of surgery. It may take 6 to 12 months for symptoms to return to baseline; in some cases, symptoms never return to baseline despite resolution of infection.</p><p>In the early post-operative period, monitoring the joint for clinical response to treatment can be challenging due to difficulty distinguishing normal post-operative pain and edema from persistent joint infection. Furthermore, after surgical debridement of the joint, signs of remaining infection are often delayed because residual microbes must multiply enough to elicit signs of infection.</p><p>Lack of wound healing may be due to infection or to other factors that affect wound healing. Inflammation of the wound may be a normal finding in the early post-operative setting. Alternatively, it may be indicative of surgical site infection, which is often unrelated to the underlying joint infection. Further discussion of factors that affect wound healing, including surgical site infection, are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/112216.html" rel="external">"Risk factors for impaired wound healing and wound complications"</a> and  <a class="medical medical_review" href="/d/html/120681.html" rel="external">"Overview of the evaluation and management of surgical site infection"</a>.)</p><p class="headingAnchor" id="H763189219"><span class="h2">Serum inflammatory markers</span><span class="headingEndMark"> — </span>We obtain serum inflammatory markers (erythrocyte sedimentation rate [ESR] and C-reactive protein [CRP]) at the beginning and end of parenteral therapy (eg, at the time of transition to oral suppressive therapy, if prescribed). If test results do not show improvement at the end of parenteral therapy, we repeat the tests again in two weeks and consider the possibility of refractory infection if results again show no improvement (see <a class="local">'Refractory infection'</a> below). We generally do not monitor serum inflammatory markers weekly during or after antibiotic therapy.</p><p>Inflammatory markers (especially the ESR) may remain elevated for prolonged periods of time following resolution of infection. Furthermore, many other conditions cause elevated inflammatory markers which can further complicate interpretation of these tests. Additional detail regarding interpretation of serum inflammatory markers is found elsewhere. (See  <a class="medical medical_review" href="/d/html/7664.html" rel="external">"Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Serum inflammatory markers'</a>.)</p><p class="headingAnchor" id="H866870811"><span class="h2">Adverse effects due to antimicrobial therapy</span><span class="headingEndMark"> — </span>Laboratory monitoring is necessary during prolonged administration of antimicrobial therapy to monitor for adverse drug effects.</p><p>For patients on parenteral antimicrobial therapy, we obtain weekly complete blood count and chemistries. Some parenteral antibiotics require additional laboratory monitoring, as detailed in the table  (<a class="graphic graphic_table graphicRef121957" href="/d/graphic/121957.html" rel="external">table 4</a>). Further details are found elsewhere. (See  <a class="medical medical_review" href="/d/html/117307.html" rel="external">"Outpatient parenteral antimicrobial therapy", section on 'Monitoring'</a>.)</p><p>For patients on oral suppressive antimicrobial therapy, we obtain a complete blood count, serum creatinine, and alanine aminotransferase at 2, 4, 8, and 12 weeks and then every 6 to 12 months thereafter.</p><p class="headingAnchor" id="H3989965283"><span class="h1">REFRACTORY INFECTION</span><span class="headingEndMark"> — </span>Clinical recognition of refractory infection can be challenging due to the lack of specificity of clinical findings and inflammatory markers, especially in the post-operative setting, as described above. (See <a class="local">'Clinical response'</a> above and <a class="local">'Serum inflammatory markers'</a> above.)</p><p>The management of refractory infections is complex. The clinical approach should involve discussions between the patient, orthopedic surgeon, infectious diseases specialist, and other providers involved in the patient's care.</p><p>If signs and symptoms of infection or elevation of serum inflammatory markers persist, we perform further workup for refractory infection, including joint aspiration and plain radiographs. Indium white blood count scanning or PET/CT scanning can be considered, if results of the workup are negative.</p><p>The diagnosis of refractory infection is confirmed by positive synovial fluid cultures that grow the same organism as recovered during the initial infection. (See  <a class="medical medical_review" href="/d/html/7664.html" rel="external">"Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p>For patients who have a confirmed refractory infection, management depends on which surgical procedure was performed to initially treat the infection (ie, whether original hardware was removed, and whether a new joint was subsequently inserted). We suggest the following approach:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients in whom the infected hardware was not removed</strong> – For these patients, we suggest removal of the hardware and a one- or two-stage exchange arthroplasty. (See <a class="local">'Two-stage exchange arthroplasty'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who initially underwent a one-stage exchange</strong> – We suggest removal of the hardware and a two-stage exchange arthroplasty for these patients. Less optimal alternatives include a repeat one-stage exchange arthroplasty or a debridement and retention of prosthesis (DAIR) procedure. (See <a class="local">'Surgical management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients who had a spacer placed for a two-stage exchange</strong> – For these patients, we remove the spacer and perform repeat debridement. Before placing a new joint, we perform additional microbiologic testing to detect residual infection (including repeat aspiration, frozen section, if available, radiographic imaging, and/or open biopsy and culture). We wait at least two weeks after the completion of parenteral antibiotics before performing microbiologic tests. (See <a class="local">'Two-stage exchange arthroplasty'</a> above.)</p><p></p><p>In all cases, a repeat course of antibiotic therapy is warranted after surgery (eg, for two-stage exchange arthroplasty, the antibiotics are given between the first stage and the second stage). Further details regarding surgical and antibiotic management are detailed above. (See <a class="local">'Surgical management'</a> above and <a class="local">'Antibiotic therapy'</a> above.)</p><p>If surgical intervention is not an option, chronic oral suppressive antibiotic therapy is indicated following completion of parenteral antibiotics. (See <a class="local">'Suppressive therapy'</a> above.)</p><p>For patients in whom refractory infection is suspected but is unable to be confirmed, clinical judgment is necessary to determine the next steps in management. We often treat patients who have clinical findings compatible with ongoing infection and persistently elevated inflammatory markers as though they have confirmed refractory infection. In the absence of clinical signs consistent with refractory infection, clinical observation may be reasonable.</p><p class="headingAnchor" id="H3293998778"><span class="h1">RECURRENT INFECTION AND REINFECTION</span><span class="headingEndMark"> — </span>Patients who have signs and symptoms of recurrent infection should always undergo a complete workup, including synovial fluid analysis and culture, as described elsewhere. (See  <a class="medical medical_review" href="/d/html/7664.html" rel="external">"Prosthetic joint infection: Epidemiology, microbiology, clinical manifestations, and diagnosis", section on 'Diagnosis'</a>.)</p><p>Recurrences may be caused by the same microorganism as the initial infection or by a different organism. When they are caused by a different organism, they are often termed "reinfections." In one study of 132 episodes of PJI, 21 of 36 nonfatal clinical failures (58 percent) were caused by a new pathogen [<a href="#rid72">72</a>]. Most failures occurred with two years of the initial infection.</p><p>The management of recurrent infections and reinfections follows the same approach as initial infections. (See <a class="local">'Surgical management'</a> above and <a class="local">'Antibiotic therapy'</a> above.)</p><p class="headingAnchor" id="H28"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Outcomes depend on the type of surgical procedure, the microbiology of infection, and individual patient circumstances. Definitions for treatment failure have been developed by expert panels [<a href="#rid73">73,74</a>]. </p><p>Overall, outcome data suggest that treatment failure occurs in 9 to 44 percent of patients [<a href="#rid10">10,70,75</a>]. The wide range of outcome data is due to many factors, including variations in study design, patient populations, clinical management, definitions of treatment failure, and duration of follow-up.</p><p>Some data suggest that the type of surgical procedure is the main variable that affects outcome [<a href="#rid22">22,72</a>]. In one study that included 200 patients with PJI and rheumatoid arthritis, the type of surgical procedure predicted the rate of survival free of treatment failure at five years of follow-up; rates for two-stage exchange, permanent resection arthroplasty, and debridement with retention of prosthesis were 79, 61, and 32 percent, respectively [<a href="#rid22">22</a>]. Treatment failure was defined as refractory or recurrent PJI confirmed by culture, histopathology, or sinus tract, death due to PJI, or PJI diagnosed at an outside hospital. </p><p class="headingAnchor" id="H34483028"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112039.html" rel="external">"Society guideline links: Osteomyelitis and prosthetic joint infection in adults"</a> and  <a class="medical medical_society_guidelines" href="/d/html/121914.html" rel="external">"Society guideline links: Outpatient parenteral antimicrobial therapy"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15809.html" rel="external">"Patient education: Deciding to have a knee replacement (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15808.html" rel="external">"Patient education: Deciding to have a hip replacement (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/716.html" rel="external">"Patient education: Joint infection (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/700.html" rel="external">"Patient education: Total hip replacement (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/704.html" rel="external">"Patient education: Total knee replacement (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>General approach</strong> – In general, management of prosthetic joint infection (PJI) consists of surgery and antimicrobial therapy. The approach depends on a number of factors including the timing and microbiology of infection, condition of the joint and implant, and individual patient circumstances. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surgical management</strong> – Surgical approaches for management of PJI include debridement and retention of prosthesis (ie, DAIR), resection arthroplasty with reimplantation (ie, one- or two-stage exchange arthroplasty), permanent resection arthroplasty, or amputation. (See <a class="local">'Surgical management'</a> above.)</p><p></p><p class="bulletIndent1">Selection of the most appropriate surgical approach depends on the patient's comorbidities, timing of original prosthetic implantation, and timing of onset of symptoms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients presenting &gt;30 days after prosthesis implantation</strong> – For these patients, definitive management consists of prosthesis removal. Options for replacement arthroplasty include one-stage or two-stage procedures. (See <a class="local">'Resection arthroplasty with reimplantation'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>One-stage exchange arthroplasty</strong> – This procedure consists of prosthesis resection with debridement of the soft tissue and bone followed by implantation of a new prosthesis during the same surgery. (See <a class="local">'One-stage exchange arthroplasty'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Two-stage exchange arthroplasty</strong> – For this method, stage one consists of prosthesis resection, debridement of soft tissue and bone, and placement of a joint spacer, followed by systemic antibiotic therapy for four to six weeks; stage two consists of implantation of a new prosthesis (see <a class="local">'Two-stage exchange arthroplasty'</a> above). This is the most common approach used in the United States. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients presenting within 30 days of prosthesis implantation or &lt;3 weeks of symptom onset</strong> – These patients may be candidates for debridement, polyethylene liner exchange, and retention of prosthesis (ie, DAIR). (See <a class="local">'Debridement and retention of prosthesis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients who do not meet criteria for reimplantation but must undergo resection for management of infection</strong> – These patients may warrant permanent resection arthroplasty. Amputation should be the last option considered. (See <a class="local">'Permanent resection arthroplasty'</a> above and <a class="local">'Amputation'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients who are not surgical candidates</strong> – This approach is warranted only for patients unable to undergo even a single surgical procedure. The patients are managed with a course of parenteral antibiotics followed by indefinite chronic oral antibiotic suppression. (See <a class="local">'Patients who are not surgical candidates'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antibiotic therapy</strong> – Antibiotic options for PJI caused by various organisms are outlined in the table  (<a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>). (See <a class="local">'Antibiotic therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For treatment of PJI due to methicillin-resistant <em>Staphylococcus aureus </em>(MRSA), we suggest <a class="drug drug_general" data-topicid="10037" href="/d/drug information/10037.html" rel="external">vancomycin</a> (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>); <a class="drug drug_general" data-topicid="9304" href="/d/drug information/9304.html" rel="external">daptomycin</a> is an acceptable alternative agent. (See <a class="local">'Staphylococcus aureus'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with staphylococcal PJI and residual hardware following surgery, we suggest adjunctive use of <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> (in combination with at least one other anti-staphylococcal agent)  (<a class="graphic graphic_table graphicRef119914" href="/d/graphic/119914.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef121445" href="/d/graphic/121445.html" rel="external">table 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Use of adjunctive rifampin'</a> above.)</p><p></p><p class="bulletIndent1">Antibiotic therapy should be tailored to culture and susceptibility data when available. The duration of therapy depends on the surgical management. (See <a class="local">'Surgical management'</a> above and <a class="local">'Suppressive therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring during treatment</strong> – Patients should undergo serial examinations in the outpatient setting to monitor for refractory or recurrent infection. Serum inflammatory markers may be helpful to detect clinical failure, but these tests are nonspecific. We suggest additional laboratory tests while patients are receiving antibiotic therapy to monitor for side effects. (See <a class="local">'Monitoring during treatment'</a> above and <a class="local">'Refractory infection'</a> above and <a class="local">'Recurrent infection and reinfection'</a> above.)</p><p></p><p class="headingAnchor" id="H193048479"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Elie Berbari, MD, FIDSA, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2013; 56:e1.</a></li><li><a class="nounderline abstract_t">Tande AJ, Gomez-Urena EO, Berbari EF, Osmon DR. Management of Prosthetic Joint Infection. Infect Dis Clin North Am 2017; 31:237.</a></li><li><a class="nounderline abstract_t">Beam E, Osmon D. Prosthetic Joint Infection Update. Infect Dis Clin North Am 2018; 32:843.</a></li><li><a class="nounderline abstract_t">Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev 2014; 27:302.</a></li><li><a class="nounderline abstract_t">Anemüller R, Belden K, Brause B, et al. Hip and Knee Section, Treatment, Antimicrobials: Proceedings of International Consensus on Orthopedic Infections. J Arthroplasty 2019; 34:S463.</a></li><li><a class="nounderline abstract_t">Biring GS, Kostamo T, Garbuz DS, et al. Two-stage revision arthroplasty of the hip for infection using an interim articulated Prostalac hip spacer: a 10- to 15-year follow-up study. J Bone Joint Surg Br 2009; 91:1431.</a></li><li><a class="nounderline abstract_t">Cui Q, Mihalko WM, Shields JS, et al. Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty. J Bone Joint Surg Am 2007; 89:871.</a></li><li><a class="nounderline abstract_t">Löwik CAM, Parvizi J, Jutte PC, et al. Debridement, Antibiotics, and Implant Retention Is a Viable Treatment Option for Early Periprosthetic Joint Infection Presenting More Than 4 Weeks After Index Arthroplasty. Clin Infect Dis 2020; 71:630.</a></li><li><a class="nounderline abstract_t">Byren I, Bejon P, Atkins BL, et al. One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome. J Antimicrob Chemother 2009; 63:1264.</a></li><li><a class="nounderline abstract_t">Zimmerli W, Widmer AF, Blatter M, et al. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group. JAMA 1998; 279:1537.</a></li><li><a class="nounderline abstract_t">El Helou OC, Berbari EF, Lahr BD, et al. Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention. Eur J Clin Microbiol Infect Dis 2010; 29:961.</a></li><li><a class="nounderline abstract_t">Huotari K, Vuorinen M, Rantasalo M. High Cure Rate for Acute Streptococcal Prosthetic Joint Infections Treated With Debridement, Antimicrobials, and Implant Retention in a Specialized Tertiary Care Center. Clin Infect Dis 2018; 67:1288.</a></li><li><a class="nounderline abstract_t">Fisman DN, Reilly DT, Karchmer AW, Goldie SJ. Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly. Clin Infect Dis 2001; 32:419.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Zimmerli W, Trampuz A, Ochsner PE. Prosthetic-joint infections. N Engl J Med 2004; 351:1645.</a></li><li><a class="nounderline abstract_t">Gómez J, Canovas E, Baños V, et al. Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant. Antimicrob Agents Chemother 2011; 55:4308.</a></li><li><a class="nounderline abstract_t">Nguyen S, Pasquet A, Legout L, et al. Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections. Clin Microbiol Infect 2009; 15:1163.</a></li><li><a class="nounderline abstract_t">Waldman BJ, Hostin E, Mont MA, Hungerford DS. Infected total knee arthroplasty treated by arthroscopic irrigation and débridement. J Arthroplasty 2000; 15:430.</a></li><li><a class="nounderline abstract_t">Senneville E, Poissy J, Legout L, et al. Safety of prolonged high-dose levofloxacin therapy for bone infections. J Chemother 2007; 19:688.</a></li><li><a class="nounderline abstract_t">Lora-Tamayo J, Murillo O, Iribarren JA, et al. A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention. Clin Infect Dis 2013; 56:182.</a></li><li><a class="nounderline abstract_t">Deirmengian C, Greenbaum J, Lotke PA, et al. Limited success with open debridement and retention of components in the treatment of acute Staphylococcus aureus infections after total knee arthroplasty. J Arthroplasty 2003; 18:22.</a></li><li><a class="nounderline abstract_t">Berbari EF, Osmon DR, Duffy MC, et al. Outcome of prosthetic joint infection in patients with rheumatoid arthritis: the impact of medical and surgical therapy in 200 episodes. Clin Infect Dis 2006; 42:216.</a></li><li><a class="nounderline abstract_t">Marculescu CE, Berbari EF, Hanssen AD, et al. Outcome of prosthetic joint infections treated with debridement and retention of components. Clin Infect Dis 2006; 42:471.</a></li><li><a class="nounderline abstract_t">Sia IG, Berbari EF, Karchmer AW. Prosthetic joint infections. Infect Dis Clin North Am 2005; 19:885.</a></li><li><a class="nounderline abstract_t">Lora-Tamayo J, Senneville É, Ribera A, et al. The Not-So-Good Prognosis of Streptococcal Periprosthetic Joint Infection Managed by Implant Retention: The Results of a Large Multicenter Study. Clin Infect Dis 2017; 64:1742.</a></li><li><a class="nounderline abstract_t">Hsieh PH, Lee MS, Hsu KY, et al. Gram-negative prosthetic joint infections: risk factors and outcome of treatment. Clin Infect Dis 2009; 49:1036.</a></li><li><a class="nounderline abstract_t">Lange J, Troelsen A, Thomsen RW, Søballe K. Chronic infections in hip arthroplasties: comparing risk of reinfection following one-stage and two-stage revision: a systematic review and meta-analysis. Clin Epidemiol 2012; 4:57.</a></li><li><a class="nounderline abstract_t">Thakrar RR, Horriat S, Kayani B, Haddad FS. Indications for a single-stage exchange arthroplasty for chronic prosthetic joint infection: a systematic review. Bone Joint J 2019; 101-B:19.</a></li><li><a class="nounderline abstract_t">Negus JJ, Gifford PB, Haddad FS. Single-Stage Revision Arthroplasty for Infection-An Underutilized Treatment Strategy. J Arthroplasty 2017; 32:2051.</a></li><li><a class="nounderline abstract_t">Marculescu CE, Berbari EF, Hanssen AD, et al. Prosthetic joint infection diagnosed postoperatively by intraoperative culture. Clin Orthop Relat Res 2005; 439:38.</a></li><li><a class="nounderline abstract_t">Zeller V, Lhotellier L, Marmor S, et al. One-stage exchange arthroplasty for chronic periprosthetic hip infection: results of a large prospective cohort study. J Bone Joint Surg Am 2014; 96:e1.</a></li><li><a class="nounderline abstract_t">Hsieh PH, Shih CH, Chang YH, et al. Two-stage revision hip arthroplasty for infection: comparison between the interim use of antibiotic-loaded cement beads and a spacer prosthesis. J Bone Joint Surg Am 2004; 86-A:1989.</a></li><li><a class="nounderline abstract_t">Mont MA, Waldman BJ, Hungerford DS. Evaluation of preoperative cultures before second-stage reimplantation of a total knee prosthesis complicated by infection. A comparison-group study. J Bone Joint Surg Am 2000; 82-A:1552.</a></li><li><a class="nounderline abstract_t">Hanssen AD, Spangehl MJ. Practical applications of antibiotic-loaded bone cement for treatment of infected joint replacements. Clin Orthop Relat Res 2004; :79.</a></li><li><a class="nounderline abstract_t">Nelson CL. The current status of material used for depot delivery of drugs. Clin Orthop Relat Res 2004; :72.</a></li><li><a class="nounderline abstract_t">Jacobs C, Christensen CP, Berend ME. Static and mobile antibiotic-impregnated cement spacers for the management of prosthetic joint infection. J Am Acad Orthop Surg 2009; 17:356.</a></li><li><a class="nounderline abstract_t">Parvizi J, Saleh KJ, Ragland PS, et al. Efficacy of antibiotic-impregnated cement in total hip replacement. Acta Orthop 2008; 79:335.</a></li><li><a class="nounderline abstract_t">Iarikov D, Demian H, Rubin D, et al. Choice and doses of antibacterial agents for cement spacers in treatment of prosthetic joint infections: review of published studies. Clin Infect Dis 2012; 55:1474.</a></li><li><a class="nounderline abstract_t">Zheng H, Barnett AG, Merollini K, et al. Control strategies to prevent total hip replacement-related infections: a systematic review and mixed treatment comparison. BMJ Open 2014; 4:e003978.</a></li><li><a class="nounderline abstract_t">Wouthuyzen-Bakker M, Kheir MM, Moya I, et al. Failure After 2-Stage Exchange Arthroplasty for Treatment of Periprosthetic Joint Infection: The Role of Antibiotics in the Cement Spacer. Clin Infect Dis 2019; 68:2087.</a></li><li><a class="nounderline abstract_t">Voleti PB, Baldwin KD, Lee GC. Use of static or articulating spacers for infection following total knee arthroplasty: a systematic literature review. J Bone Joint Surg Am 2013; 95:1594.</a></li><li><a class="nounderline abstract_t">Kusuma SK, Ward J, Jacofsky M, et al. What is the role of serological testing between stages of two-stage reconstruction of the infected prosthetic knee? Clin Orthop Relat Res 2011; 469:1002.</a></li><li><a class="nounderline abstract_t">Ghanem E, Azzam K, Seeley M, et al. Staged revision for knee arthroplasty infection: what is the role of serologic tests before reimplantation? Clin Orthop Relat Res 2009; 467:1699.</a></li><li><a class="nounderline abstract_t">Shukla SK, Ward JP, Jacofsky MC, et al. Perioperative testing for persistent sepsis following resection arthroplasty of the hip for periprosthetic infection. J Arthroplasty 2010; 25:87.</a></li><li><a class="nounderline abstract_t">Melendez DP, Greenwood-Quaintance KE, Berbari EF, et al. Evaluation of a Genus- and Group-Specific Rapid PCR Assay Panel on Synovial Fluid for Diagnosis of Prosthetic Knee Infection. J Clin Microbiol 2016; 54:120.</a></li><li><a class="nounderline abstract_t">Tan TL, Gomez MM, Manrique J, et al. Positive Culture During Reimplantation Increases the Risk of Subsequent Failure in Two-Stage Exchange Arthroplasty. J Bone Joint Surg Am 2016; 98:1313.</a></li><li><a class="nounderline abstract_t">Bejon P, Berendt A, Atkins BL, et al. Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology. J Antimicrob Chemother 2010; 65:569.</a></li><li><a class="nounderline abstract_t">George J, Kwiecien G, Klika AK, et al. Are Frozen Sections and MSIS Criteria Reliable at the Time of Reimplantation of Two-stage Revision Arthroplasty? Clin Orthop Relat Res 2016; 474:1619.</a></li><li><a class="nounderline abstract_t">Castellanos J, Flores X, Llusà M, et al. The Girdlestone pseudarthrosis in the treatment of infected hip replacements. Int Orthop 1998; 22:178.</a></li><li><a class="nounderline abstract_t">Choi HR, Freiberg AA, Malchau H, et al. The fate of unplanned retention of prosthetic articulating spacers for infected total hip and total knee arthroplasty. J Arthroplasty 2014; 29:690.</a></li><li><a class="nounderline abstract_t">Salgado CD, Dash S, Cantey JR, Marculescu CE. Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections. Clin Orthop Relat Res 2007; 461:48.</a></li><li><a class="nounderline abstract_t">Valencia JCB, Abdel MP, Virk A, et al. Destination Joint Spacers, Reinfection, and Antimicrobial Suppression. Clin Infect Dis 2019; 69:1056.</a></li><li><a class="nounderline abstract_t">Li HK, Rombach I, Zambellas R, et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection. N Engl J Med 2019; 380:425.</a></li><li><a class="nounderline abstract_t">Tice AD, Hoaglund PA, Shoultz DA. Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy. Am J Med 2003; 114:723.</a></li><li><a class="nounderline abstract_t">Youngster I, Shenoy ES, Hooper DC, Nelson SB. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting. Clin Infect Dis 2014; 59:369.</a></li><li><a class="nounderline abstract_t">Simon S, Frank BJH, Hartmann S, et al. Dalbavancin in Gram-positive periprosthetic joint infections. J Antimicrob Chemother 2022; 77:2274.</a></li><li><a class="nounderline abstract_t">Lowy FD. Staphylococcus aureus infections. N Engl J Med 1998; 339:520.</a></li><li><a class="nounderline abstract_t">Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991; 115:674.</a></li><li><a class="nounderline abstract_t">Henry NK, Rouse MS, Whitesell AL, et al. Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin. Am J Med 1987; 82:73.</a></li><li><a class="nounderline abstract_t">Scheper H, Gerritsen LM, Pijls BG, et al. Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis. Open Forum Infect Dis 2021; 8:ofab298.</a></li><li><a class="nounderline abstract_t">El Helou OC, Berbari EF, Marculescu CE, et al. Outcome of enterococcal prosthetic joint infection: is combination systemic therapy superior to monotherapy? Clin Infect Dis 2008; 47:903.</a></li><li><a class="nounderline abstract_t">Euba G, Lora-Tamayo J, Murillo O, et al. Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis. Antimicrob Agents Chemother 2009; 53:4305.</a></li><li><a class="nounderline abstract_t">Meehan AM, Osmon DR, Duffy MC, et al. Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis. Clin Infect Dis 2003; 36:845.</a></li><li><a class="nounderline abstract_t">Berbari EF, Marculescu C, Sia I, et al. Culture-negative prosthetic joint infection. Clin Infect Dis 2007; 45:1113.</a></li><li><a class="nounderline abstract_t">Shah NB, Hersh BL, Kreger A, et al. Benefits and Adverse Events Associated With Extended Antibiotic Use in Total Knee Arthroplasty Periprosthetic Joint Infection. Clin Infect Dis 2020; 70:559.</a></li><li><a class="nounderline abstract_t">Frank JM, Kayupov E, Moric M, et al. The Mark Coventry, MD, Award: Oral Antibiotics Reduce Reinfection After Two-Stage Exchange: A Multicenter, Randomized Controlled Trial. Clin Orthop Relat Res 2017; 475:56.</a></li><li><a class="nounderline abstract_t">Prendki V, Ferry T, Sergent P, et al. Prolonged suppressive antibiotic therapy for prosthetic joint infection in the elderly: a national multicentre cohort study. Eur J Clin Microbiol Infect Dis 2017; 36:1577.</a></li><li><a class="nounderline abstract_t">Keller SC, Cosgrove SE, Higgins Y, et al. Role of Suppressive Oral Antibiotics in Orthopedic Hardware Infections for Those Not Undergoing Two-Stage Replacement Surgery. Open Forum Infect Dis 2016; 3:ofw176.</a></li><li><a class="nounderline abstract_t">Siqueira MB, Saleh A, Klika AK, et al. Chronic Suppression of Periprosthetic Joint Infections with Oral Antibiotics Increases Infection-Free Survivorship. J Bone Joint Surg Am 2015; 97:1220.</a></li><li><a class="nounderline abstract_t">Bernard L, Arvieux C, Brunschweiler B, et al. Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection. N Engl J Med 2021; 384:1991.</a></li><li><a class="nounderline abstract_t">Yen HT, Hsieh RW, Huang CY, et al. Short-course versus long-course antibiotics in prosthetic joint infections: a systematic review and meta-analysis of one randomized controlled trial plus nine observational studies. J Antimicrob Chemother 2019; 74:2507.</a></li><li><a class="nounderline abstract_t">Renz N, Trampuz A, Perka C, Rakow A. Outcome and Failure Analysis of 132 Episodes of Hematogenous Periprosthetic Joint Infections-A Cohort Study. Open Forum Infect Dis 2022; 9:ofac094.</a></li><li><a class="nounderline abstract_t">Fillingham YA, Della Valle CJ, Suleiman LI, et al. Definition of Successful Infection Management and Guidelines for Reporting of Outcomes After Surgical Treatment of Periprosthetic Joint Infection: From the Workgroup of the Musculoskeletal Infection Society (MSIS). J Bone Joint Surg Am 2019; 101:e69.</a></li><li><a class="nounderline abstract_t">Diaz-Ledezma C, Higuera CA, Parvizi J. Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus. Clin Orthop Relat Res 2013; 471:2374.</a></li><li><a class="nounderline abstract_t">Chaussade H, Uçkay I, Vuagnat A, et al. Antibiotic therapy duration for prosthetic joint infections treated by Debridement and Implant Retention (DAIR): Similar long-term remission for 6 weeks as compared to 12 weeks. Int J Infect Dis 2017; 63:37.</a></li></ol></div><div id="topicVersionRevision">Topic 7665 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23223583" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28366224" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Management of Prosthetic Joint Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30241717" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prosthetic Joint Infection Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24696437" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prosthetic joint infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30348582" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Hip and Knee Section, Treatment, Antimicrobials: Proceedings of International Consensus on Orthopedic Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19880885" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Two-stage revision arthroplasty of the hip for infection using an interim articulated Prostalac hip spacer: a 10- to 15-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403814" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Antibiotic-impregnated cement spacers for the treatment of infection associated with total hip or knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504331" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Debridement, Antibiotics, and Implant Retention Is a Viable Treatment Option for Early Periprosthetic Joint Infection Presenting More Than 4 Weeks After Index Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19336454" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : One hundred and twelve infected arthroplasties treated with 'DAIR' (debridement, antibiotics and implant retention): antibiotic duration and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9605897" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20505968" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29684101" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : High Cure Rate for Acute Streptococcal Prosthetic Joint Infections Treated With Debridement, Antimicrobials, and Implant Retention in a Specialized Tertiary Care Center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11170950" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Clinical effectiveness and cost-effectiveness of 2 management strategies for infected total hip arthroplasty in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15483283" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prosthetic-joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21690277" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Linezolid plus rifampin as a salvage therapy in prosthetic joint infections treated without removing the implant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19438638" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy and tolerance of rifampicin-linezolid compared with rifampicin-cotrimoxazole combinations in prolonged oral therapy for bone and joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10884201" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Infected total knee arthroplasty treated by arthroscopic irrigation and débridement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18230552" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Safety of prolonged high-dose levofloxacin therapy for bone infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22942204" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A large multicenter study of methicillin-susceptible and methicillin-resistant Staphylococcus aureus prosthetic joint infections managed with implant retention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14560406" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Limited success with open debridement and retention of components in the treatment of acute Staphylococcus aureus infections after total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16355332" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Outcome of prosthetic joint infection in patients with rheumatoid arthritis: the impact of medical and surgical therapy in 200 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421790" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Outcome of prosthetic joint infections treated with debridement and retention of components.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16297738" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prosthetic joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28369296" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The Not-So-Good Prognosis of Streptococcal Periprosthetic Joint Infection Managed by Implant Retention: The Results of a Large Multicenter Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19691430" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Gram-negative prosthetic joint infections: risk factors and outcome of treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22500127" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Chronic infections in hip arthroplasties: comparing risk of reinfection following one-stage and two-stage revision: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30648487" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Indications for a single-stage exchange arthroplasty for chronic prosthetic joint infection: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28390887" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Single-Stage Revision Arthroplasty for Infection-An Underutilized Treatment Strategy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16205135" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Prosthetic joint infection diagnosed postoperatively by intraoperative culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24382729" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : One-stage exchange arthroplasty for chronic periprosthetic hip infection: results of a large prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15342762" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Two-stage revision hip arthroplasty for infection: comparison between the interim use of antibiotic-loaded cement beads and a spacer prosthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11097443" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Evaluation of preoperative cultures before second-stage reimplantation of a total knee prosthesis complicated by infection. A comparison-group study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15552141" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Practical applications of antibiotic-loaded bone cement for treatment of infected joint replacements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15552140" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The current status of material used for depot delivery of drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19474445" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Static and mobile antibiotic-impregnated cement spacers for the management of prosthetic joint infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18622836" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy of antibiotic-impregnated cement in total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22918993" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Choice and doses of antibacterial agents for cement spacers in treatment of prosthetic joint infections: review of published studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24604480" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Control strategies to prevent total hip replacement-related infections: a systematic review and mixed treatment comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30281077" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Failure After 2-Stage Exchange Arthroplasty for Treatment of Periprosthetic Joint Infection: The Role of Antibiotics in the Cement Spacer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24005200" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Use of static or articulating spacers for infection following total knee arthroplasty: a systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20941647" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : What is the role of serological testing between stages of two-stage reconstruction of the infected prosthetic knee?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19241115" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Staged revision for knee arthroplasty infection: what is the role of serologic tests before reimplantation?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20732621" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Perioperative testing for persistent sepsis following resection arthroplasty of the hip for periprosthetic infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26537446" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Evaluation of a Genus- and Group-Specific Rapid PCR Assay Panel on Synovial Fluid for Diagnosis of Prosthetic Knee Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27489323" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Positive Culture During Reimplantation Increases the Risk of Subsequent Failure in Two-Stage Exchange Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20053693" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Two-stage revision for prosthetic joint infection: predictors of outcome and the role of reimplantation microbiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26689583" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Are Frozen Sections and MSIS Criteria Reliable at the Time of Reimplantation of Two-stage Revision Arthroplasty?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728312" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The Girdlestone pseudarthrosis in the treatment of infected hip replacements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23932758" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : The fate of unplanned retention of prosthetic articulating spacers for infected total hip and total knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17534195" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Higher risk of failure of methicillin-resistant Staphylococcus aureus prosthetic joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30689767" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Destination Joint Spacers, Reinfection, and Antimicrobial Suppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30699315" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Oral versus Intravenous Antibiotics for Bone and Joint Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12829198" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Outcomes of osteomyelitis among patients treated with outpatient parenteral antimicrobial therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24785233" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35678452" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Dalbavancin in Gram-positive periprosthetic joint infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709046" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Staphylococcus aureus infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1929035" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3578332" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34258321" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Outcome of Debridement, Antibiotics, and Implant Retention for Staphylococcal Hip and Knee Prosthetic Joint Infections, Focused on Rifampicin Use: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18754743" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Outcome of enterococcal prosthetic joint infection: is combination systemic therapy superior to monotherapy?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19667290" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Pilot study of ampicillin-ceftriaxone combination for treatment of orthopedic infections due to Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12652384" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Outcome of penicillin-susceptible streptococcal prosthetic joint infection treated with debridement and retention of the prosthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17918072" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Culture-negative prosthetic joint infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30944931" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Benefits and Adverse Events Associated With Extended Antibiotic Use in Total Knee Arthroplasty Periprosthetic Joint Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27387759" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : The Mark Coventry, MD, Award: Oral Antibiotics Reduce Reinfection After Two-Stage Exchange: A Multicenter, Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28378243" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Prolonged suppressive antibiotic therapy for prosthetic joint infection in the elderly: a national multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27747252" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Role of Suppressive Oral Antibiotics in Orthopedic Hardware Infections for Those Not Undergoing Two-Stage Replacement Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26246256" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Chronic Suppression of Periprosthetic Joint Infections with Oral Antibiotics Increases Infection-Free Survivorship.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34042388" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Antibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31050758" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Short-course versus long-course antibiotics in prosthetic joint infections: a systematic review and meta-analysis of one randomized controlled trial plus nine observational studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35355896" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Outcome and Failure Analysis of 132 Episodes of Hematogenous Periprosthetic Joint Infections-A Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31318814" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Definition of Successful Infection Management and Guidelines for Reporting of Outcomes After Surgical Treatment of Periprosthetic Joint Infection: From the Workgroup of the Musculoskeletal Infection Society (MSIS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23440616" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Success after treatment of periprosthetic joint infection: a Delphi-based international multidisciplinary consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28804007" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Antibiotic therapy duration for prosthetic joint infections treated by Debridement and Implant Retention (DAIR): Similar long-term remission for 6 weeks as compared to 12 weeks.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
